




CELLULAR TOXICITY OF A NANOSTRUCTURED EMULSION OF AMPHOTERICIN B.

Lilian Sosa\*, Marcelle de Silva Abreu, María Rincón, Carolina Espinoza, Diana Berenguer, Cristina Riera and Ana Calpena


**Introduction**

Amphotericin B (AmB) is a potent polyene macrolide antibiotic with high molecular weight (924 Da) and broad-spectrum coverage (1). From a physicochemical point of view, AmB is a poorly hydrosoluble, amphoteric, amphiphilic molecule and is difficult to solubilize in organic solvents. For this reason, there is no topical formulation of AmB commercially available at the moment (2). This fact evidences the need to develop new formulations using excipients with permeation-enhancing properties in order to facilitate the penetration of drug into Stratum Corneum (SC) and its distribution from SC to epidermis and dermis.





**Methods and materials**

We have developed an AmB nanoemulsion 0,3% (NE) having as composition: Labrasol® / pluro®5: 1, castor oil® and Transcutol-P® with the following proportions: 55-05-40 (3). To determine the toxicity of this formulation, we have performed cytotoxicity tests through the technique WST-1 (cell proliferation regente WST-1 from Roche®) on two cell lines: Raw 264.7 of murine tumor origin and J774 of mouse monocytic tumor origin. Both cell lines were provided by Eucelbanc (Faculty of Biology, UB), respectively. Cytotoxicity tests were performed with: A solution of AmB dissolved in DMSO, the AmB NE and the blank (NE without AmB).




RAW 264,7 (RPMI)  
J774 (MEM)  
SBF  
37 °C, 5 % CO<sub>2</sub>



**Results**

Table 1. Citotoxicity Concentration about AmB solution, AmB NE and NE (blank)

| Compounds                       | CC50 µg/mL   |               |
|---------------------------------|--------------|---------------|
|                                 | RAW          | J774          |
| AmB Solution<br>150-0,14(µg/mL) | 56,34 ± 0,29 | 57,80 ± 0,24  |
| NE AmB<br>150-0,14(µg/mL)       | 95,76 ± 0,28 | 342,13 ± 0,23 |
| Formulation                     | CC50 % p/p   |               |
| NE<br>12,5-0,02 (%)             | > 12,50      | 38,94 ± 0,20  |



The results obtained indicate that the AmB NE presented lower cellular toxicity than the AmB in solution in both Cell lines and greater toxicity in J774 cells. The NE without drug was not toxic against raw cells and presented cellular toxicity against J774 cells at a concentration of 38,94 ± 0,20 µg/mL (Table 1). As a future perspective, we will conduct these tests on keratinocytes (HaCaT).

\*CONTACT PERSON:

Directorate for Scientific, Humanistic and Technological Research (DICTH), National Autonomous University of Honduras. liliansosa2012@gmail.com lilian.sosa@unah.edu.hn

REFERENCES

1. Gray KC, Palacios DS, Dailey I, Endo MM, Uno BE, Wilcock BC, et al. Amphotericin primarily kills yeast by simply binding ergosterol. Proc Natl Acad Sci U SA 2012;109:2234-9.
2. Pérez AP, Altube MJ, Schilre P, Apezteguia G, Celes FS, Zacchino S, et al. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity *in vitro*. Colloids Surf. B Biointerfaces 2016, 139, 190–198.
3. Sosa L, Clares B, Alvarado HL, Bozal N, Domenech O and Calpena AC. Amphotericin B releasing topical nanoemulsion for the treatment of candidiasis and aspergillosis. Nanomedicine 2017, 13, 2303–2312